Interest in the Medical Services Dengue Fever Test Kit Continues to Grow
August 23 2007 - 3:40PM
PR Newswire (US)
EDMONTON, Alberta, Aug. 23 /PRNewswire-FirstCall/ -- Medical
Services International Inc. (Pink Sheets: MSITF) wishes to announce
that interest in its VScan Dengue Fever kit continues to increase.
Originally, the Company had projected that it would sell
approximately 250,000 VScan Dengue Fever tests in the latest fiscal
year. Based on independent inquiries and orders from distributors
the Company has increased its projections for Dengue Fever test
kits to 400,000. While not a significant number of kits, it will
generate substantial cashflow. The number of countries indicating
that Dengue Fever is a becoming a problem is growing each year. As
the accuracy of the VScan Dengue Fever test kit becomes known, the
number of test kits required will increase. The Company is in a
position to take advantage of the growth. In most countries, it
takes 3 to 6 weeks to get test results due to the specialized
testing equipment required. The Dengue Fever kit gives results in
20 minutes and costs less than 15% of any current test. About VScan
The VScan rapid test kit is a single use, disposable, accurate,
cost effective, easy to use, test for the screening of HIV1&2,
Tuberculosis (TB), Hepatitis B&C, Dengue Fever, West Nile,
Syphilis. Malaria and Prostate Cancer. The kits cannot be sold in
Canada. Medical Services International Inc. trades in the United
States on the NQB Pink Sheets under the symbol "MSITF". For further
information, please contact Robert Talbot at (780) 430 6363 or
http://www.medicalservicesintl.com/ or
http://www.minerva-biotech.com/. NOTE: Certain statements in this
press release are "forward-looking statements" within the meaning
of the Private Securities Act of 1995. Such statements involve
known and unknown risks, uncertainties and other factors that may
cause results to differ materially. Such risks, uncertainties and
other factors include but are not limited to new economic
conditions, risk in product development, market acceptance of new
products and continuing product demand, level of competition and
other factors described in Company reports and other filings with
regulatory bodies DATASOURCE: Medical Services International Inc.
CONTACT: Robert Talbot of Medical Services International Inc.,
+1-780-430-6363 Web site: http://www.medicalservicesintl.com/
http://www.minerva-biotech.com/
Copyright